Annual earnings and new shelf registration reshape Relay Therapeutics story

Relay Therapeutics (RLAY) has just reported its full year 2025 results, pairing higher reported revenue and a smaller net loss with a new US$96.2 million shelf registration for potential common stock issuance.

The earnings update, new US$96.2 million shelf registration and recent conference appearance come as Relay Therapeutics’ share price trades at US$9.89, with a 90 day share price return of 30.47% and a 1 year total shareholder return above 200%. However, the 3 and 5 year total shareholder returns remain negative, suggesting recent momentum has picked up after a tougher longer term record.

If this kind of rebound in sentiment has your attention, it could be a good moment to scan 32 healthcare AI stocks for other healthcare names using AI where the market may be reassessing the outlook.

With revenue at US$15.36 million, a net loss of US$276.48 million and the share price well below the average analyst target, is Relay Therapeutics still cheap or is the market already pricing in future growth?

Preferred price to book of 3.1x, is it justified?

Relay Therapeutics currently trades on a P/B of 3.1x, which appears inexpensive compared with its high-value peer set but sits above the broader US biotech group.

The P/B ratio compares the company’s market value to its net assets on the balance sheet. In effect, investors are paying 3.1 times book value for each $1 of equity today. For a clinical stage business that is still loss making, this often reflects how the market weighs its pipeline, intellectual property and partnerships against ongoing cash burn.

Relative to peers carrying an average P/B of 68.2x, Relay Therapeutics looks far less expensive. This indicates that some investors are paying much higher prices for similar balance sheet backing elsewhere. At the same time, its 3.1x multiple is described as more expensive than the 2.7x average for the US biotech industry, so the market is pricing in more optimism than the sector overall, even though it remains far below the highest-rated names.

Result: Price to book ratio of 3.1x (ABOUT RIGHT)

However, you still need to weigh the ongoing US$276.48 million net loss and the potential impact of future equity issuance from the US$96.2 million shelf.

Next Steps

If you are torn between the upbeat tone around recent price action and the clear risks in the numbers, now is a good time to look through the data yourself and decide where you stand. Then weigh 2 key rewards and 2 important warning signs to see how that balance of concerns and potential upside fits your own view.

Ready to scout your next idea?

If Relay Therapeutics has sharpened your focus, do not stop here. Use the Simply Wall St screener to line up your next set of candidates before the crowd moves on.

• Zero in on companies the market might be overlooking with screener containing 24 high quality undiscovered gems that pair strong fundamentals with limited current attention.
• Strengthen your downside protection by checking 66 resilient stocks with low risk scores that score well on balance sheet and risk metrics.
• Target quality at a sensible price through 50 high quality undervalued stocks that combine solid cash flows with supportive valuations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.